← Back to Clinical Trials
Recruiting NCT06290167

NCT06290167 A New 360° Dual-task Based Protocol for the Pre-clinical In-hospital and At-home Rehabilitation of Elderly: DUAL-Rehab

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06290167
Status Recruiting
Phase
Sponsor Istituto Auxologico Italiano
Condition Cognitive Decline
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2023-07-03
Primary Completion 2026-04-10

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
360° mediaTreatment As Usual (TAU)In hospital sessions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2023-07-03 with a primary completion date of 2026-04-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The main objective of this project is two-fold 1. to develop a Dual-Task training exploiting the potentiality of the 360° technology in terms of interactivity and ecological validity 2. to investigate its efficacy in improving the cognitive functioning in a randomized clinical trial for 2 different populations: subjects with subjective memory complaints and mild cognitive impairment. Specifically, participants will follow an integrated training including 2 phases: 1)in-hospital rehabilitation, where subjects will be provided sessions of the training in immersive modality; 2)at-home rehabilitation, where older adults will be asked to perform at home the non-immersive version of the training using a tablet. Expected outcome is an improvement in cognitive functioning (assessed with a complete neuropsychological battery) after the training, thus advancing literature about non-pharmacological interventions in the preclinical stages of dementia along with innovative technical instruments.

Eligibility Criteria

Inclusion Criteria (group of SMC): * \> 65 years old * self-reported memory complaints * score on Mini-Mental State Examination greater than or equal to 27/30 (normal range) Exclusion Criteria: * no evidence of objective impairments on the neuropsychological testing, scores on the Clinical Dementia Rating \< 0.5 Inclusion Criteria (group of MCI): * \> 65 years old * a self-reported (or reported by a caregiver) cognitive decline * an objective impairment on the neuropsychological testing * scores on the Clinical Dementia Rating \< 0.5. Exclusion Criteria: * no dementia

Contact & Investigator

Central Contact

Elisa Pedroli, PsyD

✉ e.pedroli@auxologico.it

📞 02 61911 2707

Frequently Asked Questions

Who can join the NCT06290167 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Cognitive Decline. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06290167 currently recruiting?

Yes, NCT06290167 is actively recruiting participants. Contact the research team at e.pedroli@auxologico.it for enrollment information.

Where is the NCT06290167 trial being conducted?

This trial is being conducted at Milan, Italy.

Who is sponsoring the NCT06290167 clinical trial?

NCT06290167 is sponsored by Istituto Auxologico Italiano. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology